Pharmaceuticals, Biotechnology and Life Sciences
Started proof-of-concept Phase 2 clinical trial with ELX-02 in up to eight Alport syndrome patients with nonsense mutations; topline results…
SYDNEY, Australia and FLORHAM PARK, N.J., Nov. 10, 2022 (GLOBE NEWSWIRE) — Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company…
– Significant Reduction in Operating Expenses – Strategic Alternatives Process Ongoing Total Net Sales of $0.4 Million, Including $0.3 Million…
–Reported encouraging clinical data supporting the differentiated mode-of action of Theriva’s novel oncolytic adenovirus (OV) platform– –Received clearance from the…
SAN CARLOS, Calif., Nov. 10, 2022 (GLOBE NEWSWIRE) — SAN CARLOS, Calif., November 10, 2022 (GLOBE NEWSWIRE) — Atreca, Inc.…
MIAMI, FL, Nov. 09, 2022 (GLOBE NEWSWIRE) — Veru Inc. (NASDAQ: VERU), a biopharmaceutical company focused on developing novel medicines…
NEW YORK, NY, Nov. 08, 2022 (GLOBE NEWSWIRE) — Enzo Biochem, Inc. (NYSE: ENZ) (“Enzo” or the “Company”), a leading…
ROCKVILLE, Md., Nov. 08, 2022 (GLOBE NEWSWIRE) — Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and…
Results reflect strong growth across all leading prescription products, including IXINITY, Rupall, and Gleolan Management to host conference call at…
Patient enrollment completed for Phase 3 non-erosive gastroesophageal reflux disease (NERD) daily dosing trial with topline data for primary endpoint…